Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs
Conditions
Interventions
Canakinumab
Placebo
Locations
65
United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Ann Arbor, Michigan, United States
Novartis Investigative Site
Cleveland, Ohio, United States
Novartis Investigative Site
Edegem, Antwerpen, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Hasselt, Belgium
Start Date
June 27, 2014
Primary Completion Date
July 4, 2017
Completion Date
July 4, 2017
Last Updated
May 17, 2018
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions